Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(-)-10,11-dihydro-10-hydroxy carbamazepine.
about
A review of eslicarbazepine acetate for the adjunctive treatment of partial-onset epilepsyA chiral liquid chromatography method for the simultaneous determination of oxcarbazepine, eslicarbazepine, R-licarbazepine and other new chemical derivatives BIA 2-024, BIA 2-059 and BIA 2-265, in mouse plasma and brain.Pharmacokinetics and drug interactions of eslicarbazepine acetate.Update on treatment of partial onset epilepsy: role of eslicarbazepineEfficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies.Clinical utility of eslicarbazepine: current evidence.Effects of eslicarbazepine acetate on acute and chronic latrunculin A-induced seizures and extracellular amino acid levels in the mouse hippocampusEslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action.Real-world data on eslicarbazepine acetate as add-on to antiepileptic monotherapyNew antiepileptic drugs that are second generation to existing antiepileptic drugs.Bioequivalence of eslicarbazepine acetate from two different sources of its active product ingredient in healthy subjects.Pharmacotherapy of epilepsy: newly approved and developmental agents.Novel medications for epilepsy.Eslicarbazepine acetate for partial-onset seizures.Carbonyl reduction pathways in drug metabolism.Pharmacokinetic/pharmacodynamic evaluation of eslicarbazepine for the treatment of epilepsy.A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures.Metabolic profile and safety of piperlongumine.Eslicarbazepine Acetate: A New Improvement on a Classic Drug Family for the Treatment of Partial-Onset Seizures.[Anticonvulsant add-on therapy with Eslicarbazepine acetate : Results of the EPOS-study in adults in Germany].Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy.Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers.Oxcarbazepine does not suppress cortical spreading depression.Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans.Pharmacodynamic and pharmacokinetic interaction studies of loreclezole with felbamate, lamotrigine, topiramate, and oxcarbazepine in the mouse maximal electroshock seizure model.Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers.Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescents with epilepsy.Eslicarbazepine acetate: a new option for the treatment of focal epilepsyEslicarbazepine Acetate: A Double-blind, Add-on, Placebo-controlled Exploratory Trial in Adult Patients with Partial-onset Seizures
P2860
Q24621327-5953949D-22FC-475D-81D3-BEB1258813E6Q33968508-2B4E44C1-EC87-4D79-B5C1-72F587912191Q34276263-EE64ADD5-F482-4256-9197-46D69FA45D56Q34329823-2A9B68D7-32AB-445E-B078-EBF4ED5016C5Q34375311-A255E838-50FB-463B-9A8D-E8D19C549587Q35087964-B7A39670-DA84-4E75-9746-5CFDCBCDBFA4Q35531026-C996BB55-4130-4D99-9637-9DFBD2F53C24Q35664957-CEC396E1-15D1-4E88-A7D0-FFBB7EB2C826Q35936036-9242AB47-3B59-4F00-8C02-2ED6677A0D54Q36491829-9E3E3B45-CB61-483A-A272-02F051BD5870Q36947574-CBC9CB7D-AEED-4475-954C-E3DE9590F91EQ37831297-9420776E-753B-4108-8DCE-52DBA64AB8FDQ37950518-19DC923F-0547-497D-AA0B-FD43DB5C26DAQ37957121-2A8B182A-EEE4-4880-B00F-EAFC688D60F4Q38156452-CDB1A061-19E3-4C69-A9CD-037926B7B695Q38367761-921D47AA-7AF1-4589-A82B-091E6B4BE8A6Q38542064-A0302B61-3600-419C-BB81-4765B01BACE4Q39343548-9170DE8C-8AF5-400D-8A9B-6E7647096D8FQ39456360-FCE8DB88-673A-4D6A-8153-11A74FD3FE2FQ40611807-33F5C28B-88AE-40C0-8838-CC208C85EC79Q42956261-44D70711-1696-4BCC-8855-CC6269831CD6Q44062629-52E5DD8B-6BD9-4809-A59E-CD904A7562F2Q44769570-5426D938-AFCE-4C9E-9746-3AD88A4F7769Q45001572-ED6BFFB6-AFB7-4503-BF55-8296AE15DA64Q45282313-65F25291-E0AF-403B-9AC1-405C481329ECQ46265751-E604A26E-BBA4-48D4-97A7-6B38FE341037Q46570612-615D1F97-116E-4D48-BB19-B67DDB83DA0BQ58870328-C503F6A1-3646-47E3-9F4A-5850D27D3707Q59284846-2DF9FA29-F15B-45C2-A947-9B4CEE27B914
P2860
Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(-)-10,11-dihydro-10-hydroxy carbamazepine.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Metabolism of two new antiepil ...... ydro-10-hydroxy carbamazepine.
@en
Metabolism of two new antiepil ...... ydro-10-hydroxy carbamazepine.
@nl
type
label
Metabolism of two new antiepil ...... ydro-10-hydroxy carbamazepine.
@en
Metabolism of two new antiepil ...... ydro-10-hydroxy carbamazepine.
@nl
prefLabel
Metabolism of two new antiepil ...... ydro-10-hydroxy carbamazepine.
@en
Metabolism of two new antiepil ...... ydro-10-hydroxy carbamazepine.
@nl
P1433
P1476
Metabolism of two new antiepil ...... ydro-10-hydroxy carbamazepine.
@en
P2093
P304
P356
10.1016/S0920-1211(01)00231-5
P577
2001-05-01T00:00:00Z